Everything below concerns Cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
This will invoke the component's search function, passing "your query" and "strict" as arguments. This type of invocation is well-suited for Ajax-enabled applications. ColdFusion 8 introduced the ability to serialize ColdFusion data structures to JSON for consumption on the client. The ColdFusion server will automatically generate documentation for a component if you navigate to its URL and insert the appropriate code within the component's declarations. This is an application of component introspection, available to developers of ColdFusion components. Access to a component's documentation requires a password. A developer can view the documentation for all components known to the ColdFusion server by navigating to the ColdFusion URL. This interface resembles the Javadoc HTML documentation for Java classes.
== SU == su – (s) Sundanese language (ISO 639-1 code) SU (s) Soviet Union (ISO 3166 digram; obsolete 1992) Sudan (FIPS 10-4 country code) SUB – (i) Student Union Building SuD – (a) Subject under Discussion SUDC – Swedish United Dawah Center, a salafist Islamic organisation in Sweden SUI (a) Sonic user interface (s) Switzerland (IOC and FIFA trigram, but not ISO 3166) SUK – Start Up Kit sun – (s) Sundanese language (ISO 639-2 code) SUN – (s) Soviet Union (ISO 3166 trigram; obsolete 1992) Stanford University Network that led to Sun Microsystems SUNY – (a) State University of New York (usually pronounced "sue-knee") SUR – (s) Suriname (ISO 3166 trigram) SURTASS – (p) Surveillance Towed Array Sensor System SUSAT – (a) Sight Unit Small Arms, Trilux SUV – (i) Sport Utility Vehicle
For a definitive diagnosis to be made, symptoms must occur within 6 hours of transfusion, hypoxemia must be present, there must be radiographic evidence of bilateral infiltrates and there must be no evidence of left atrial hypertension (fluid overload). It occurs in 15% of the transfused patient with mortality rate of 5 to 10%. Recipient risk factors includes: end-stage liver disease, sepsis, haematological malignancies, sepsis, and ventilated patients. Antibodies to human neutrophil antigens (HNA) and human leukocyte antigens (HLA) have been associated with this type of transfusion reaction. Donor's antibodies interacting with antigen positive recipient tissue result in release of inflammatory cytokines, resulting in pulmonary capillary leakage. The treatment is supportive. Transfusion associated circulatory overload (TACO) is a common, yet underdiagnosed, reaction to blood product transfusion consisting of the new onset or exacerbation of three of the following within 6 hours of cessation of transfusion: acute respiratory distress, elevated brain natriuretic peptide (BNP), elevated central venous pressure (CVP), evidence of left heart failure, evidence of positive fluid balance, and/or radiographic evidence of pulmonary vascular congestion. Patients with congestive heart failure or kidney disease are more susceptible to volume overload. For especially vulnerable patients, a standard RBC unit could be split by sterile technique in the blood bank and administered over 8 hours instead of the standard 4 hours.
catalyst Any chemical species or substance whose presence increases the reaction rate of one or more particular chemical reactions but which is itself unchanged by the reaction, being neither a reactant nor a product of the reaction. Catalysts often need only be present in very low concentrations relative to the reactants in order for catalysis to occur. They may be simple molecules which catalyze reactions spontaneously, though most biochemical reactions are catalyzed by specifically evolved enzymes which allow them to proceed at rates millions or billions of times faster than they otherwise would.
== Functions == LCRs were originally thought as 'junk' regions or as neutral linkers between domains; however, experimental and computational evidence increasingly indicates that they may play important adaptive and conserved roles, relevant to biotechnology, heterologous protein expression, medicine, as well as to our understanding of protein evolution. LCRs of eukaryotic proteins have been involved in human diseases, especially neurodegenerative ones, where they tend to form amyloids in humans and other eukaryotes. They have been reported to have adhesive roles, function in excreted sticky proteins used for prey capture, or have roles as transducers of molecular movement, e.g. in the prokaryotic TonB/TolA systems. LCRs may form surfaces for interaction with phospholipid bilayers, or as positive charge clusters for DNA binding, or as negative or even histidine-acidic charge clusters for coordinating calcium, magnesium or zinc ions. They may also play important roles in protein translation, as tRNA 'sponges', slowing down translation in order to allow time for the correct folding of the nascent polypeptide chain. They may even function as frame-shift checkpoints, by shifting to an unusual amino acid content that makes the protein highly unstable or insoluble, which in turn triggers fast recycling, before any further cellular damage.
Sources: en.wikipedia.org
Research and development as well as production, however, remain at the Herisau site. Metrohm AG moved from the town center of Herisau in 2011 to its new premises in the industrial zone "Hölzli". The new premises were expanded in 2015 to accommodate the growing number of employees. In summer 2024, Metrohm expanded its Herisau campus by an additional 20,000 square meters. In 2025, Metrohm established new subsidiaries in Korea, Portugal and Ghana.
Middleton is dyslexic. He read from the New Revised Standard Version of the Bible at the 2011 wedding of his sister Catherine to Prince William. In 2019, he disclosed his struggles with depression and attention deficit hyperactivity disorder, which he attributed to public scrutiny from age 23 as a result of his eldest sister's relationship. He sought treatment in 2017, undertaking cognitive behavioral therapy. Middleton also spent "restorative time" at the Glen Affric Estate, where he has hosted deer-stalking parties. The estate is owned by his sister Philippa's father-in-law. In the same year, he penned a column in the Daily Mail about mental health. Middleton is an ambassador for the Pets As Therapy charity and has credited his dog, Ella, for helping him through his depression. He breeds dogs, owning six, as well as one rescue lamb. Middleton also keeps bees on the grounds of Bucklebury Manor. In April 2020, he founded the Paw Print Fund in aid of animal welfare charities. Middleton was in a relationship with actress Donna Air from 2013 to 2018. Middleton met French financial analyst Alizée Thevenet (b. 30 November 1989) in 2018. She is the daughter of retired diplomat Jean-Gabriel Thevenet. Middleton and Alizée announced their engagement in September 2019. On 11th September 2021, Alizée's mother, along with James's family, attended the wedding in the village of Bormes-les-Mimosas in the south of France where Alizée's family lives. Alizée's father had died some months before the wedding.
=== Cardiac muscle === Cardiac muscle is slightly different from skeletal muscle. At rest, they prefer to utilize fatty acids as their main energy source. As activity increases and it begins to pump faster, the cardiac muscles begin to oxidize glucose at a higher rate. An analysis of mRNA levels of GLUT1 and GLUT4 in cardiac muscles show that GLUT1 plays a larger role in cardiac muscles than it does in skeletal muscles. GLUT4, however, is still believed to be the primary transporter for glucose. Much like in other tissues, GLUT4 also responds to insulin signaling, and is transported into the plasma membrane to facilitate the diffusion of glucose into the cell.
Wenzel Model was developed to calculate the dependence that surface roughness has on the observed contact angle. Surfaces that are not atomically smooth will exhibit an observed contact angle that varies from the actual contact angle of the surface. The equation is expressed as:
In digital circuits and machine learning, a one-hot is a group of bits among which the legal combinations of values are only those with a single high (1) bit and all the others low (0). A similar implementation in which all bits are '1' except one '0' is sometimes called one-cold. In statistics, dummy variables represent a similar technique for representing categorical data.
Sources: en.wikipedia.org
== Genetics == Amyloid-beta precursor protein is an ancient and highly conserved protein. In humans, the gene APP is located on chromosome 21 and contains 18 exons spanning 290 kilobases. Several alternative splicing isoforms of APP have been observed in humans, ranging in length from 639 to 770 amino acids, with certain isoforms preferentially expressed in neurons; changes in the neuronal ratio of these isoforms have been associated with Alzheimer's disease. Homologous proteins have been identified in other organisms such as Drosophila (fruit flies), C. elegans (roundworms), and all mammals. The amyloid beta region of the protein, located in the membrane-spanning domain, is not well conserved across species and has no obvious connection with APP's native-state biological functions. Mutations in critical regions of amyloid precursor protein, including the region that generates amyloid beta, cause familial susceptibility to Alzheimer's disease. For example, several mutations outside the Aβ region associated with familial Alzheimer's have been found to dramatically increase production of Aβ. A mutation (A673T) in the APP gene protects against Alzheimer's disease. This substitution is adjacent to the beta secretase cleavage site and results in a 40% reduction in the formation of amyloid beta in vitro.
Multivalent nanoparticles, bearing multiple targeting groups, can cluster receptors, which can activate cellular signaling pathways, and give stronger anchoring. Monovalent nanoparticles, bearing a single binding site, avoid clustering and so are preferable for tracking the behavior of individual proteins. It has been shown that catalytic activity and sintering rates of a functionalized nanoparticle catalyst is correlated to nanoparticles' number density Coatings that mimic those of red blood cells can help nanoparticles evade the immune system.
== Structure == OpLuc is a complex of two covalently bonded protein subunits: two molecules of 19 kDa and two molecules of 35 kDa components, making it a heterotetrameric molecule. The proteins signal the enzyme for secretion in luminescence, catalyzed by the protein 19 kDa. The luciferase has many cysteine residues that stabilize the enzyme in extracellular environments using disulfide bonds.
=== Pathology === As a bioactive lipid, ceramide has been implicated in a variety of physiological functions including apoptosis, cell growth arrest, differentiation, cell senescence, cell migration and adhesion. Roles for ceramide and its downstream metabolites have also been suggested in a number of pathological states including cancer, neurodegeneration, diabetes, microbial pathogenesis, obesity, and inflammation. Several distinct ceramides potently predict major adverse cardiovascular events (MACE), namely C16:0, C18:0, and C24:1, although C24:0 has an inverse relationship. C16-C18 are harmful in the liver. Ceramide levels are positively correlated with inflammation and oxidative stress in the liver, and the onset and progression of non-alcoholic fatty liver disease (NAFLD) is associated with elevated ceramide in hepatocytes. Dietary intake of saturated fat has been shown to increase serum ceramide and increase insulin resistance. Although initial studies showed increased insulin resistance in muscle, subsequent studies also showed increased insulin resistance in liver and adipose tissue. Interventions that limit ceramide synthesis or increase ceramide degradation lead to improved health (reduced insulin resistance and reduced fatty liver disease, for example). Ceramides induce skeletal muscle insulin resistance when synthesized as a result of saturated fat activation of TLR4 receptors. Unsaturated fat does not have this effect. Ceramides induce insulin resistance in many tissues by inhibition of Akt/PKB signaling.
[...] It is this practice of allowing one set of people to dictate to another set of people what they shall do, what they shall think, what they shall drink, when they shall go to bed, what they shall buy, and where they shall buy it, what wages they shall get and how they shall spend them, against which the Liberal party have always protested. The political terms of "modern", "progressive" or "new" Liberalism began to appear in the mid to late 1880s and became increasingly common to denote the tendency in the Liberal Party to favour an increased role for the state as more important than the classical liberal stress on self-help and freedom of choice. By the early 20th century, the Liberals stance began to shift towards "New Liberalism", what would today be called social liberalism, namely a belief in personal liberty with a support for government intervention to provide social welfare. This shift was best exemplified by the Liberal government of H. H. Asquith and his Chancellor David Lloyd George, whose Liberal reforms in the early 1900s created a basic welfare state. David Lloyd George adopted a programme at the 1929 general election entitled We Can Conquer Unemployment!, although by this stage the Liberals had declined to third-party status. The Liberals as expressed in the Liberal Yellow Book now regarded opposition to state intervention as being a characteristic of right-wing extremists.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.